NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free BIOR Stock Alerts $0.73 -0.01 (-1.35%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7550-Day Range$0.60▼$1.3352-Week Range$0.59▼$6.70Volume219,984 shsAverage Volume211,326 shsMarket Capitalization$26.18 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biora Therapeutics alerts: Email Address Biora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,955.6% Upside$15.00 Price TargetShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.46) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector873rd out of 922 stocksPharmaceutical Preparations Industry404th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingBiora Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiora Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Biora Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.52% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 4.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 1.7 News and Social Media Coverage News SentimentBiora Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for BIOR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.97% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biora Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($1.46) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biora Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Biora Therapeutics Stock (NASDAQ:BIOR)Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More BIOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Stock News HeadlinesMay 18 at 5:36 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Biora Therapeutics (NASDAQ:BIOR)May 16 at 2:37 PM | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16 at 2:37 PM | finance.yahoo.comBIOR: BT-600 Data in JuneMay 16 at 9:37 AM | msn.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Call TranscriptMay 16 at 8:07 AM | finance.yahoo.comBiora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 15 at 6:44 PM | msn.comBiora Therapeutics GAAP EPS of -$0.14 beats by $0.31, revenue of $0.54MMay 15 at 4:12 PM | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15 at 4:05 PM | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | americanbankingnews.comBiora Therapeutics (BIOR) Set to Announce Earnings on WednesdayMay 8, 2024 | americanbankingnews.comBiora Therapeutics (NASDAQ:BIOR) Trading Down 1.5%May 7, 2024 | finance.yahoo.comBiora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate UpdateMay 6, 2024 | globenewswire.comBiora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024April 30, 2024 | globenewswire.comBiora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600April 18, 2024 | msn.comBiora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51April 15, 2024 | nasdaq.comBiora Therapeutics, Inc. Common Stock (BIOR)April 10, 2024 | stockhouse.comBiora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery TechnologyApril 9, 2024 | markets.businessinsider.comBiora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery InnovationsApril 8, 2024 | globenewswire.comBiora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery TechnologyApril 4, 2024 | markets.businessinsider.comBiora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock DownApril 4, 2024 | globenewswire.comBiora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform DevelopmentApril 3, 2024 | globenewswire.comBiora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 2, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | finance.yahoo.comBiora Therapeutics Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | msn.comPrecision Biosciences, Mesoblast, Pulse Biosciences among healthcare moversApril 1, 2024 | marketwatch.comBiora Therapeutics Shares Drop 26% After Pricing of Direct OfferingSee More Headlines Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/17/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+1,955.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,110,000.00 Net MarginsN/A Pretax Margin-3,110,600.00% Return on EquityN/A Return on Assets-163.19% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual Sales$4,000.00 Price / Sales6,546.14 Cash FlowN/A Price / Cash FlowN/A Book Value($3.64) per share Price / Book-0.20Miscellaneous Outstanding Shares35,884,000Free Float17,594,000Market Cap$26.18 million OptionableOptionable Beta1.22 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 57)CEO & Director Comp: $984.14kMr. Eric d'Esparbes (Age 56)Chief Financial Officer Comp: $748.26kMr. Clarke Neumann J.D. (Age 60)Senior VP, General Counsel & Secretary Comp: $724.62kEric FoxVP of Finance & Accounting & TreasurerMr. Troy Seelye (Age 60)Chief Information Officer Mr. George Gianakopoulos (Age 63)Senior Vice President of Sales Ms. Robyn HattonHead of Human ResourcesMr. Kevin Howe Ph.D.Senior VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 65)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMore ExecutivesKey CompetitorsJanOneNASDAQ:JANNanoViricidesNYSE:NNVCAcasti PharmaNASDAQ:ACSTEnlivex TherapeuticsNASDAQ:ENLVUnity BiotechnologyNASDAQ:UBXView All Competitors BIOR Stock Analysis - Frequently Asked Questions Should I buy or sell Biora Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks. What is Biora Therapeutics' stock price target for 2024? 1 analysts have issued 1-year price objectives for Biora Therapeutics' stock. Their BIOR share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,955.6% from the stock's current price. View analysts price targets for BIOR or view top-rated stocks among Wall Street analysts. How have BIOR shares performed in 2024? Biora Therapeutics' stock was trading at $1.35 at the beginning of the year. Since then, BIOR stock has decreased by 45.9% and is now trading at $0.7297. View the best growth stocks for 2024 here. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our BIOR earnings forecast. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.03. When did Biora Therapeutics' stock split? Biora Therapeutics shares reverse split before market open on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L and Surbhi Sarna. View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOR) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
